{
"instance": {
"adap-20190630x10q.htm": {
"axisCustom": 0,
"axisStandard": 12,
"contextCount": 98,
"dts": {
"calculationLink": {
"local": [
"adap-20190630_cal.xml"
]
},
"definitionLink": {
"local": [
"adap-20190630_def.xml"
],
"remote": [
"http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
"http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
]
},
"inline": {
"local": [
"adap-20190630x10q.htm"
]
},
"labelLink": {
"local": [
"adap-20190630_lab.xml"
],
"remote": [
"http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
"https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
]
},
"presentationLink": {
"local": [
"adap-20190630_pre.xml"
]
},
"referenceLink": {
"remote": [
"http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
"https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
]
},
"schema": {
"local": [
"adap-20190630.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
"http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
"http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
"http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
"https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
"http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
"http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
]
}
},
"elementCount": 299,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2019-01-31": 6,
"http://www.adaptimmune.com/20190630": 1,
"http://xbrl.sec.gov/dei/2019-01-31": 5,
"total": 12
},
"keyCustom": 20,
"keyStandard": 245,
"memberCustom": 10,
"memberStandard": 15,
"nsprefix": "adap",
"nsuri": "http://www.adaptimmune.com/20190630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"p",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "00090 - Document - Document and Entity Information",
"role": "http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation",
"shortName": "Document and Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NatureOfOperations",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10101 - Disclosure - General",
"role": "http://www.adaptimmune.com/role/DisclosureGeneral",
"shortName": "General",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:NatureOfOperations",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
"role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
"shortName": "Summary of Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10301 - Disclosure - Revenue",
"role": "http://www.adaptimmune.com/role/DisclosureRevenue",
"shortName": "Revenue",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeasesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10401 - Disclosure - Operating Leases",
"role": "http://www.adaptimmune.com/role/DisclosureOperatingLeases",
"shortName": "Operating Leases",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeasesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10501 - Disclosure - Other expense, net",
"role": "http://www.adaptimmune.com/role/DisclosureOtherExpenseNet",
"shortName": "Other expense, net",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10601 - Disclosure - Loss per share",
"role": "http://www.adaptimmune.com/role/DisclosureLossPerShare",
"shortName": "Loss per share",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10701 - Disclosure - Accumulated other comprehensive income (loss)",
"role": "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLoss",
"shortName": "Accumulated other comprehensive income (loss)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10801 - Disclosure - Fair value measurements",
"role": "http://www.adaptimmune.com/role/DisclosureFairValueMeasurements",
"shortName": "Fair value measurements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "10901 - Disclosure - Available-for-sale debt securities",
"role": "http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecurities",
"shortName": "Available-for-sale debt securities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherCurrentAssetsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "11001 - Disclosure - Other current assets",
"role": "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssets",
"shortName": "Other current assets",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherCurrentAssetsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00100 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
"role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "11101 - Disclosure - Accrued expenses and other current liabilities",
"role": "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
"shortName": "Accrued expenses and other current liabilities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "11201 - Disclosure - Share-based compensation",
"role": "http://www.adaptimmune.com/role/DisclosureShareBasedCompensation",
"shortName": "Share-based compensation",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
"role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
"shortName": "Summary of Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"reportCount": 1,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
"role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
"shortName": "Summary of Significant Accounting Policies (Tables)",
"subGroupType": "tables",
"uniqueAnchor": null
},
"R24": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30303 - Disclosure - Revenue (Tables)",
"role": "http://www.adaptimmune.com/role/DisclosureRevenueTables",
"shortName": "Revenue (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"us-gaap:LesseeOperatingLeasesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30403 - Disclosure - Operating Leases (Tables)",
"role": "http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables",
"shortName": "Operating Leases (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:LesseeOperatingLeasesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30503 - Disclosure - Other expense, net (Tables)",
"role": "http://www.adaptimmune.com/role/DisclosureOtherExpenseNetTables",
"shortName": "Other expense, net (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"us-gaap:ComprehensiveIncomeNoteTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"reportCount": 1,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30703 - Disclosure - Accumulated other comprehensive income (loss) (Tables)",
"role": "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLossTables",
"shortName": "Accumulated other comprehensive income (loss) (Tables)",
"subGroupType": "tables",
"uniqueAnchor": null
},
"R28": {
"firstAnchor": {
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30803 - Disclosure - Fair value measurements (Tables)",
"role": "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsTables",
"shortName": "Fair value measurements (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "30903 - Disclosure - Available-for-sale debt securities (Tables)",
"role": "http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesTables",
"shortName": "Available-for-sale debt securities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00105 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
"role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"us-gaap:OtherCurrentAssetsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "31003 - Disclosure - Other current assets (Tables)",
"role": "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsTables",
"shortName": "Other current assets (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:OtherCurrentAssetsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "31103 - Disclosure - Accrued expenses and other current liabilities (Tables)",
"role": "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
"shortName": "Accrued expenses and other current liabilities (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "31203 - Disclosure - Share-based compensation (Tables)",
"role": "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables",
"shortName": "Share-based compensation (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R33": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RetainedEarningsAccumulatedDeficit",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40101 - Disclosure - General (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureGeneralDetails",
"shortName": "General (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R34": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_1_1_2019_b0fK2nGeyU-KDMIyD6w4Qg",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Basis of Presentation (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationDetails",
"shortName": "Summary of Significant Accounting Policies - Basis of Presentation (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R35": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_1_1_2019_b0fK2nGeyU-KDMIyD6w4Qg",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Leases - General Information (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails",
"shortName": "Summary of Significant Accounting Policies - Leases - General Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_1_1_2019_srt_RestatementAxis_srt_RestatementAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_a9TdeahjEEO3dtZT2uxx8Q",
"decimals": "-5",
"lang": null,
"name": "us-gaap:OperatingLeaseRightOfUseAsset",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:LeaseCostTableTextBlock",
"us-gaap:LesseeOperatingLeasesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Leases - Cash Flow and cost (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesCashFlowAndCostDetails",
"shortName": "Summary of Significant Accounting Policies - Leases - Cash Flow and cost (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R37": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeaseRightOfUseAsset",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40204 - Disclosure - Summary of Significant Accounting Policies - Leases - Balance Sheet Information (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesBalanceSheetInformationDetails",
"shortName": "Summary of Significant Accounting Policies - Leases - Balance Sheet Information (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R38": {
"firstAnchor": {
"ancestors": [
"p",
"adap:AccountingChangesAndErrorCorrectionsPolicyTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "3",
"first": true,
"lang": null,
"name": "us-gaap:DebtWeightedAverageInterestRate",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_pure_6qI6peH2K0-6xcH_AX6OoA",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40205 - Disclosure - Summary of Significant Accounting Policies - Correction of an immaterial error (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCorrectionOfImmaterialErrorDetails",
"shortName": "Summary of Significant Accounting Policies - Correction of an immaterial error (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"adap:AccountingChangesAndErrorCorrectionsPolicyTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "3",
"first": true,
"lang": null,
"name": "us-gaap:DebtWeightedAverageInterestRate",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_pure_6qI6peH2K0-6xcH_AX6OoA",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"b",
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40301 - Disclosure - Revenue - Revenue from contracts with customers (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails",
"shortName": "Revenue - Revenue from contracts with customers (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:RevenueFromContractWithCustomerTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": "-5",
"lang": null,
"name": "adap:TransactionPriceContractWithCustomers",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"b",
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00200 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
"role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"lang": null,
"name": "us-gaap:ResearchAndDevelopmentExpense",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:LeaseCostTableTextBlock",
"us-gaap:LesseeOperatingLeasesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeaseCost",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40401 - Disclosure - Operating Leases (Details)-Lease Cost",
"role": "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsLeaseCost",
"shortName": "Operating Leases (Details)-Lease Cost",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"b",
"p",
"td",
"tr",
"table",
"us-gaap:LeaseCostTableTextBlock",
"us-gaap:LesseeOperatingLeasesTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"lang": null,
"name": "us-gaap:LeaseCost",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R41": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40402 - Disclosure - Operating Leases (Details)-Maturities",
"role": "http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities",
"shortName": "Operating Leases (Details)-Maturities",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"ix:continuation",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
"us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40501 - Disclosure - Other expense, net (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails",
"shortName": "Other expense, net (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
"us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"p",
"us-gaap:EarningsPerShareTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_T0FLYQxkvkOUsLHDDS0_fg",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_shares_BiDdvOFInU6PA4EZOiKkYg",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40601 - Disclosure - Loss per share - Antidilutive securities (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSecuritiesDetails",
"shortName": "Loss per share - Antidilutive securities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:EarningsPerShareTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adap_EmployeeConsultantsAndDirectorsStockOptionsMember_T0FLYQxkvkOUsLHDDS0_fg",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_shares_BiDdvOFInU6PA4EZOiKkYg",
"xsiNil": "false"
}
},
"R44": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"us-gaap:ComprehensiveIncomeNoteTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40701 - Disclosure - Accumulated other comprehensive income (loss) (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLossDetails",
"shortName": "Accumulated other comprehensive income (loss) (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"us-gaap:ComprehensiveIncomeNoteTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R45": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40801 - Disclosure - Fair value measurements (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails",
"shortName": "Fair value measurements (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4rUfkc0o2kOmSXLkDewENg",
"decimals": "-3",
"lang": null,
"name": "us-gaap:TradingSecuritiesDebt",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R46": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
"us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "40901 - Disclosure - Available-for-sale debt securities (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails",
"shortName": "Available-for-sale debt securities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_12_31_2018_5YgthZK9G06LI1xPF6P-_Q",
"decimals": "-5",
"lang": null,
"name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R47": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
"us-gaap:OtherCurrentAssetsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:IncomeTaxesReceivable",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "41001 - Disclosure - Other current assets (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails",
"shortName": "Other current assets (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
"us-gaap:OtherCurrentAssetsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:IncomeTaxesReceivable",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R48": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "adap:AccruedLiabilitiesForPurchasesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "41101 - Disclosure - Accrued expenses and other current liabilities (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
"shortName": "Accrued expenses and other current liabilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
"us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_6_30_2019_1W2HRAYDsE6ghK9FkCgaGg",
"decimals": "-3",
"first": true,
"lang": null,
"name": "adap:AccruedLiabilitiesForPurchasesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R49": {
"firstAnchor": {
"ancestors": [
"b",
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "41201 - Disclosure - Share-based compensation - Share-based Compensation Expense (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
"shortName": "Share-based compensation - Share-based Compensation Expense (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"b",
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"b",
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00300 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
"role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"lang": null,
"name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R50": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_shares_BiDdvOFInU6PA4EZOiKkYg",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "41202 - Disclosure - Share-based compensation - Options (Details)",
"role": "http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails",
"shortName": "Share-based compensation - Options (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_shares_BiDdvOFInU6PA4EZOiKkYg",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00305 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)",
"role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eN7TUZZt2U-7xUixoD7jOA",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGE IN EQUITY",
"role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGE IN EQUITY",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "As_Of_12_31_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eN7TUZZt2U-7xUixoD7jOA",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_4_1_2019_To_6_30_2019_RU6nTezmxk6KiGChYcQGmw",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
"reportCount": 1,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00405 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGE IN EQUITY (PARENTHETICAL)",
"role": "http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquityParenthetical",
"shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGE IN EQUITY (PARENTHETICAL)",
"subGroupType": "",
"uniqueAnchor": null
},
"R9": {
"firstAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "00500 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
"role": "http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows",
"shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"p",
"td",
"tr",
"table",
"div",
"div",
"body",
"html"
],
"baseRef": "adap-20190630x10q.htm",
"contextRef": "Duration_1_1_2019_To_6_30_2019_ZjdVitpqk0Sim3p-1Fog-Q",
"decimals": "-3",
"first": true,
"lang": null,
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unique": true,
"unitRef": "Unit_Standard_USD_UdTyyAjPuE6QvOt3hYW8xw",
"xsiNil": "false"
}
}
},
"segmentCount": 25,
"tag": {
"adap_AccountingChangesAndErrorCorrectionsPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for accounting changes and error corrections.",
"label": "Accounting Changes and Error Corrections [Policy Text Block]",
"terseLabel": "Correction of an immaterial error to the incremental borrowing rate"
}
}
},
"localname": "AccountingChangesAndErrorCorrectionsPolicyTextBlock",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"adap_AccruedLiabilitiesForPurchasesCurrent": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Liabilities For Purchases, Current",
"terseLabel": "Accrued clinical and development expenditure"
}
}
},
"localname": "AccruedLiabilitiesForPurchasesCurrent",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"adap_AgencyBondMaturityPeriodThreeMonthsToOneYearMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the information pertains to maturity period of agency bond.",
"label": "Agency Bond Maturity Period Three Months To One Year [Member]",
"terseLabel": "Agency Bond Maturity Period Three Months To One Year"
}
}
},
"localname": "AgencyBondMaturityPeriodThreeMonthsToOneYearMember",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"adap_AvailableForSaleSecuritiesDebtMaturityPeriod": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Information pertains to maturity period of corporate debt securities",
"label": "Available For Sale Securities Debt Maturity Period"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtMaturityPeriod",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "durationItemType"
},
"adap_CertificateOfDepositMaturityPeriodLessThanThreeMonthsMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the information pertains to certificate of deposit maturity period less than three months.",
"label": "Certificate Of Deposit Maturity Period Less Than Three Months [Member]",
"terseLabel": "Certificate of Deposit Maturity Period Less Than Three Months"
}
}
},
"localname": "CertificateOfDepositMaturityPeriodLessThanThreeMonthsMember",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"adap_CertificateOfDepositMaturityPeriodThreeMonthsToOneYearMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the information pertains to maturity period of certificate of deposit.",
"label": "Certificate Of Deposit Maturity Period Three Months To One Year [Member]",
"terseLabel": "Certificate of Deposit Maturity Period Three Months To One Year"
}
}
},
"localname": "CertificateOfDepositMaturityPeriodThreeMonthsToOneYearMember",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"adap_ClinicalMaterialsCurrent": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": {
"order": 1.0,
"parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Clinical materials for use in research and development with alternative future use expected to be consumed within one year or the normal operating cycle.",
"label": "Clinical Materials Current",
"terseLabel": "Clinical materials"
}
}
},
"localname": "ClinicalMaterialsCurrent",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"adap_ClinicalMaterialsNoncurrent": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Clinical materials for use in research and development with alternative future use not expected to be consumed within the normal operating cycle.",
"label": "Clinical Materials, Noncurrent",
"terseLabel": "Clinical materials"
}
}
},
"localname": "ClinicalMaterialsNoncurrent",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"adap_CommonStockSharesOutstandingAdjustedBalance": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Common Stock, Shares Outstanding, Adjusted Balance",
"label": "Common Stock, Shares Outstanding, Adjusted Balance",
"terseLabel": "Beginning balance as adjusted, shares"
}
}
},
"localname": "CommonStockSharesOutstandingAdjustedBalance",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "sharesItemType"
},
"adap_ContractWithCustomerLiabilityAmountsInvoicedInPeriod": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from amounts invoiced in the period",
"label": "Contract with Customer, Liability, Amounts Invoiced in the Period",
"terseLabel": "Amounts invoiced in the period"
}
}
},
"localname": "ContractWithCustomerLiabilityAmountsInvoicedInPeriod",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "monetaryItemType"
},
"adap_ContractWithCustomerLiabilityForeignExchangeOnConsolidation": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from foreign exchange on consolidation.",
"label": "Contract with Customer, Liability, Foreign Exchange on Consolidation",
"verboseLabel": "Foreign exchange arising on consolidation"
}
}
},
"localname": "ContractWithCustomerLiabilityForeignExchangeOnConsolidation",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "monetaryItemType"
},
"adap_ContractWithCustomerLiabilityRevenueRecognitionPeriod": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "The period over which the revenue should be recognized from contract with customer liability.",
"label": "Contract with Customer Liability, Revenue Recognition Period",
"terseLabel": "Revenue recognition period"
}
}
},
"localname": "ContractWithCustomerLiabilityRevenueRecognitionPeriod",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "durationItemType"
},
"adap_CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the information pertains to maturity period of less than three months.",
"label": "Corporate Debt Securities Maturity Period Less Than Three Months [Member]",
"terseLabel": "Corporate Debt Securities Maturity Period Less Than Three Months"
}
}
},
"localname": "CorporateDebtSecuritiesMaturityPeriodLessThanThreeMonthsMember",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"adap_CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the information pertains to maturity period of corporate debt securities",
"label": "Corporate Debt Securities Maturity Period Three Months To One Year [Member]",
"terseLabel": "Corporate Debt Securities Maturity Period Three Months To One Year"
}
}
},
"localname": "CorporateDebtSecuritiesMaturityPeriodThreeMonthsToOneYearMember",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"adap_DevelopmentAndServiceMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the information pertaining to development services.",
"label": "Development And Service [Member]",
"terseLabel": "Development revenue"
}
}
},
"localname": "DevelopmentAndServiceMember",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "domainItemType"
},
"adap_DocumentAndEntityInformationAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Document and Entity Information [Abstract]"
}
}
},
"localname": "DocumentAndEntityInformationAbstract",
"nsuri": "http://www.adaptimmune.com/20190630",
"xbrltype": "stringItemType"
},
"adap_EmployeeConsultantsAndDirectorsStockOptionsMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
"label": "Employee Consultants And Directors Stock Options [Member]",
"terseLabel": "Share options"
}
}
},
"localname": "EmployeeConsultantsAndDirectorsStockOptionsMember",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"adap_GlaxosmithklineIntellectualPropertyDevelopmentLtdMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "GlaxoSmithKline Intellectual Property Development Ltd.",
"label": "Glaxosmithkline Intellectual Property Development Ltd [Member]",
"terseLabel": "GlaxoSmithKline Intellectual Property Development Ltd"
}
}
},
"localname": "GlaxosmithklineIntellectualPropertyDevelopmentLtdMember",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "domainItemType"
},
"adap_IncreaseDecreaseInCurrentAssets": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 9.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The increase (decrease) during the reporting period in accounts receivable and other operating assets due within one year (or one business cycle).",
"label": "Increase (Decrease) in Current Assets",
"negatedLabel": "Increase in receivables and other operating assets"
}
}
},
"localname": "IncreaseDecreaseInCurrentAssets",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"adap_IncreaseDecreaseInOperatingLeaseLiability": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the opearting lease liability due to change in borrowing rate.",
"label": "Increase Decrease In Operating Lease Liability",
"terseLabel": "Reduction in lease liability"
}
}
},
"localname": "IncreaseDecreaseInOperatingLeaseLiability",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCorrectionOfImmaterialErrorDetails"
],
"xbrltype": "monetaryItemType"
},
"adap_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the right-of-use asset due to change in borrowing rate.",
"label": "Increase Decrease In Operating Lease Right Of Use Asset",
"terseLabel": "Reduction in right-of-use asset"
}
}
},
"localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCorrectionOfImmaterialErrorDetails"
],
"xbrltype": "monetaryItemType"
},
"adap_IncreaseDecreaseInPayablesAndDeferredRevenue": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received, the amount of obligations and expenses incurred but not paid and the amount of deferred revenue.",
"label": "Increase (Decrease) in Payables and Deferred Revenue",
"terseLabel": "Increase (decrease) in payables and deferred revenue"
}
}
},
"localname": "IncreaseDecreaseInPayablesAndDeferredRevenue",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"adap_MarketableSecuritiesMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the information pertains to marketable securities",
"label": "Marketable Securities [Member]",
"terseLabel": "Marketable securities"
}
}
},
"localname": "MarketableSecuritiesMember",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"adap_MoneyMarketFundsOfShortTermDebtSecuritiesLessThanThreeMonthsMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the information pertains to money market funds of short-term debt securities less than three months.",
"label": "Money Market Funds Of Short Term Debt Securities Less Than Three Months [Member]",
"terseLabel": "Money Market Funds Maturity Period Less Than Three Months"
}
}
},
"localname": "MoneyMarketFundsOfShortTermDebtSecuritiesLessThanThreeMonthsMember",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"adap_NumberOfContractsWithCustomer": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the total number of contracts with customers.",
"label": "Number of Contracts with Customer",
"terseLabel": "Number of contracts with customers"
}
}
},
"localname": "NumberOfContractsWithCustomer",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "integerItemType"
},
"adap_NumberOfCustomers": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the number of customers.",
"label": "Number of customers",
"terseLabel": "Number of customers"
}
}
},
"localname": "NumberOfCustomers",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "integerItemType"
},
"adap_NumberOfGeographicLocations": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Represents the number of geographic locations.",
"label": "Number Of Geographic Locations",
"terseLabel": "Number of geographic locations"
}
}
},
"localname": "NumberOfGeographicLocations",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "integerItemType"
},
"adap_OperatingLeaseAssetLiabilityNet": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesBalanceSheetInformationDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Operating lease asset (liability), net",
"label": "Operating lease asset (liability), net",
"negatedTotalLabel": "Total operating lease liabilities"
}
}
},
"localname": "OperatingLeaseAssetLiabilityNet",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesBalanceSheetInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"adap_OtherNonoperatingIncomeExpenseOther": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails": {
"order": 4.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of other income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income (Expense), Other",
"terseLabel": "Other"
}
}
},
"localname": "OtherNonoperatingIncomeExpenseOther",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails"
],
"xbrltype": "monetaryItemType"
},
"adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the nominal exercise price.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value, With Nominal Exercise Price",
"terseLabel": "Weighted average fair value of options with a nominal exercise price"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueWithNominalExercisePrice",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails"
],
"xbrltype": "perShareItemType"
},
"adap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Gross number of share options (or share units) granted with nominal exercise price during the period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, With Nominal Exercise Price Grants in Period, Gross",
"terseLabel": "Number of additional options with a nominal exercise price granted"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWithNominalExercisePriceGrantsInPeriodGross",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails"
],
"xbrltype": "sharesItemType"
},
"adap_TransactionPriceContractWithCustomers": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The aggregate transaction price from contract with customers.",
"label": "Transaction Price, Contract with Customers",
"terseLabel": "Transaction price"
}
}
},
"localname": "TransactionPriceContractWithCustomers",
"nsuri": "http://www.adaptimmune.com/20190630",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "monetaryItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
"label": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r232"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r233"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCountry": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "ISO 3166-1 alpha-2 country code.",
"label": "Entity Address, Country"
}
}
},
"localname": "EntityAddressCountry",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "countryCodeItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r234"
],
"lang": {
"en-US": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r234"
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r234"
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r235"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r234"
],
"lang": {
"en-US": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r234"
],
"lang": {
"en-US": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r234"
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r230"
],
"lang": {
"en-US": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r231"
],
"lang": {
"en-US": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DocumentDocumentAndEntityInformation"
],
"xbrltype": "tradingSymbolItemType"
},
"srt_MajorCustomersAxis": {
"auth_ref": [
"r95",
"r141",
"r145",
"r226"
],
"lang": {
"en-US": {
"role": {
"label": "Customer [Axis]"
}
}
},
"localname": "MajorCustomersAxis",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "stringItemType"
},
"srt_MaximumMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Maximum [Member]",
"terseLabel": "Maximum"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Minimum [Member]",
"terseLabel": "Minimum"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"srt_NameOfMajorCustomerDomain": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Name Of Major Customer [Domain]",
"terseLabel": "Customer [Domain]"
}
}
},
"localname": "NameOfMajorCustomerDomain",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "domainItemType"
},
"srt_ProductOrServiceAxis": {
"auth_ref": [
"r94",
"r141",
"r144",
"r224",
"r225"
],
"lang": {
"en-US": {
"role": {
"label": "Product and Service [Axis]"
}
}
},
"localname": "ProductOrServiceAxis",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"srt_ProductsAndServicesDomain": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Products And Services [Domain]",
"terseLabel": "Product and Service [Domain]"
}
}
},
"localname": "ProductsAndServicesDomain",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Statistical Measurement [Axis]"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Range [Member]",
"terseLabel": "Statistical Measurement [Domain]"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"srt_RestatementAdjustmentMember": {
"auth_ref": [
"r73",
"r74",
"r75",
"r76"
],
"lang": {
"en-US": {
"role": {
"label": "Restatement Adjustment [Member]",
"terseLabel": "Restatement Adjustment"
}
}
},
"localname": "RestatementAdjustmentMember",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails"
],
"xbrltype": "domainItemType"
},
"srt_RestatementAxis": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Restatement [Axis]"
}
}
},
"localname": "RestatementAxis",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails"
],
"xbrltype": "stringItemType"
},
"srt_RestatementDomain": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Restatement [Domain]",
"terseLabel": "Restatement [Domain]"
}
}
},
"localname": "RestatementDomain",
"nsuri": "http://fasb.org/srt/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Summary of Significant Accounting Policies"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_AccountingStandardsUpdate201602Member": {
"auth_ref": [
"r191"
],
"lang": {
"en-US": {
"role": {
"documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
"label": "Accounting Standards Update201602 [Member]",
"terseLabel": "ASU 2016-02"
}
}
},
"localname": "AccountingStandardsUpdate201602Member",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
"label": "Accrued Expenses and Other Current Liabilities Disclosure [Text Block]",
"terseLabel": "Accrued expenses and other current liabilities"
}
}
},
"localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Accrued expenses and other current liabilities"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r25"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable, Current",
"terseLabel": "Accounts payable"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsReceivableNetCurrent": {
"auth_ref": [
"r1",
"r16",
"r96",
"r97",
"r142"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
"label": "Accounts Receivable, Net, Current",
"terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $0 and $0"
}
}
},
"localname": "AccountsReceivableNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedLiabilitiesCurrent": {
"auth_ref": [
"r27"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Liabilities, Current",
"totalLabel": "Total",
"verboseLabel": "Accrued expenses and other accrued liabilities"
}
}
},
"localname": "AccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
"auth_ref": [
"r24",
"r132"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
"label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
"terseLabel": "Property, plant and equipment, accumulated depreciation"
}
}
},
"localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
"auth_ref": [
"r36",
"r37",
"r38",
"r43",
"r46"
],
"lang": {
"en-US": {
"role": {
"documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
"label": "Accumulated Net Unrealized Investment Gain Loss [Member]",
"terseLabel": "Accumulated unrealized gains (losses) on available-for-sale debt securities"
}
}
},
"localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r40",
"r42",
"r43"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
"terseLabel": "Accumulated other comprehensive loss"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r39",
"r43",
"r46",
"r173"
],
"lang": {
"en-US": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "Accumulated Other Comprehensive Income [Member]",
"terseLabel": "Accumulated other comprehensive loss"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedTranslationAdjustmentMember": {
"auth_ref": [
"r35",
"r43",
"r46",
"r173"
],
"lang": {
"en-US": {
"role": {
"documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
"label": "Accumulated Translation Adjustment [Member]",
"terseLabel": "Accumulated foreign currency translation adjustments"
}
}
},
"localname": "AccumulatedTranslationAdjustmentMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r17"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
"label": "Additional Paid-in Capital",
"terseLabel": "Additional paid in capital"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid In Capital [Member]",
"terseLabel": "Additional paid in capital"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
"auth_ref": [
"r72"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by new accounting pronouncement.",
"label": "Adjustments for New Accounting Pronouncements [Axis]"
}
}
},
"localname": "AdjustmentsForNewAccountingPronouncementsAxis",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"auth_ref": [
"r150",
"r151",
"r161",
"r162"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
"label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
"terseLabel": "Share-based compensation expense"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
}
}
},
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r151",
"r158",
"r160"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "Allocated Share-based Compensation Expense",
"terseLabel": "Total share-based compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
"auth_ref": [
"r20",
"r98",
"r113"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
"label": "Allowance for Doubtful Accounts Receivable, Current",
"terseLabel": "Allowance for doubtful accounts"
}
}
},
"localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfIntangibleAssets": {
"auth_ref": [
"r66",
"r128",
"r130"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
"label": "Amortization of Intangible Assets",
"verboseLabel": "Amortization"
}
}
},
"localname": "AmortizationOfIntangibleAssets",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r78"
],
"lang": {
"en-US": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
"verboseLabel": "Potentially dilutive equity instruments excluded from the diluted loss per share (in shares)"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSecuritiesDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"auth_ref": [
"r78"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by type of antidilutive security.",
"label": "Antidilutive Securities [Axis]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
"terseLabel": "Antidilutive Securities"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"auth_ref": [
"r78"
],
"lang": {
"en-US": {
"role": {
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
"label": "Antidilutive Securities Name [Domain]",
"terseLabel": "Antidilutive Securities, Name [Domain]"
}
}
},
"localname": "AntidilutiveSecuritiesNameDomain",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r92",
"r211",
"r217"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "Assets",
"verboseLabel": "Assets:"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r3",
"r5",
"r33"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Assets, Current [Abstract]",
"terseLabel": "Current assets"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
"auth_ref": [
"r105"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax",
"terseLabel": "Gross unrealized gains"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
"auth_ref": [
"r106"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails": {
"order": 3.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax",
"negatedLabel": "Gross unrealized losses"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
"auth_ref": [
"r103",
"r119"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Available-for-sale Debt Securities, Amortized Cost Basis",
"totalLabel": "Amortized cost"
}
}
},
"localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Available-for-sale debt securities"
}
}
},
"localname": "AvailableForSaleSecuritiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
"auth_ref": [
"r99",
"r104",
"r119"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails": {
"order": 1.0,
"parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Available-for-sale Securities, Debt Securities",
"terseLabel": "Aggregate estimated fair value"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtSecurities",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
"auth_ref": [
"r102",
"r119"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
"label": "Available-for-sale Securities, Debt Securities, Current",
"terseLabel": "Marketable securities - available-for-sale debt securities",
"totalLabel": "Available-for-sale securities, Debt Securities, Current, Total"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis of Accounting, Policy [Policy Text Block]",
"terseLabel": "Basis of presentation"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
"auth_ref": [
"r71"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
"label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
"terseLabel": "Summary of Significant Accounting Policies"
}
}
},
"localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r0",
"r23",
"r68"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash And Cash Equivalents [Member]",
"terseLabel": "Cash equivalents"
}
}
},
"localname": "CashAndCashEquivalentsMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r63",
"r68",
"r69"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
"periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
"periodStartLabel": "Cash, cash equivalents and restricted cash at start of period"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r63",
"r189"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash Cash Equivalents Restricted Cash And Restricted CashEquivalentsPeriod Increase Decrease Including Exchange Rate Effect",
"totalLabel": "Net decrease in cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CertificatesOfDepositAtCarryingValue": {
"auth_ref": [
"r23"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails": {
"order": 1.0,
"parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
"label": "Certificates of Deposit, at Carrying Value",
"terseLabel": "Certificate of deposit"
}
}
},
"localname": "CertificatesOfDepositAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ChangeInContractWithCustomerLiabilityAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Change in Contract with Customer, Liability [Abstract]",
"terseLabel": "Change in contract with customer, liability"
}
}
},
"localname": "ChangeInContractWithCustomerLiabilityAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common stock"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r15"
],
"lang": {
"en-US": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common stock, par value"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r15"
],
"lang": {
"en-US": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common stock, shares authorized"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r15"
],
"lang": {
"en-US": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"terseLabel": "Common stock, shares issued"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesOutstanding": {
"auth_ref": [
"r15",
"r135"
],
"lang": {
"en-US": {
"role": {
"documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
"label": "Common Stock, Shares, Outstanding",
"periodEndLabel": "Balance at the end of the period, shares",
"periodStartLabel": "Balance at the beginning of the period, shares",
"terseLabel": "Common stock, shares outstanding"
}
}
},
"localname": "CommonStockSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r15"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock, Value, Issued",
"verboseLabel": "Common stock - Ordinary shares par value ?0.001, 785,857,300 authorized and 630,672,578 issued and outstanding (2018: 701,103,126 authorized and 627,454,270 issued and outstanding)"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r48",
"r50",
"r51"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
"totalLabel": "Total comprehensive loss for the period"
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNoteTextBlock": {
"auth_ref": [
"r59"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
"label": "Comprehensive Income (Loss) Note [Text Block]",
"terseLabel": "Accumulated other comprehensive income (loss)"
}
}
},
"localname": "ComprehensiveIncomeNoteTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLoss"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ContractWithCustomerAssetAndLiabilityAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Contract with Customer, Asset and Liability [Abstract]",
"terseLabel": "Contract assets, liability and receivables"
}
}
},
"localname": "ContractWithCustomerAssetAndLiabilityAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
"auth_ref": [
"r139"
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of contract balances and changes in contract balances.",
"label": "Contract with Customer, Asset and Liability [Table Text Block]",
"verboseLabel": "Schedule of movements in deferred revenue"
}
}
},
"localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ContractWithCustomerLiability": {
"auth_ref": [
"r137",
"r138",
"r142"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
"label": "Contract with Customer, Liability",
"periodEndLabel": "Deferred revenue at end of the period",
"periodStartLabel": "Deferred revenue at beginning of the period"
}
}
},
"localname": "ContractWithCustomerLiability",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityCurrent": {
"auth_ref": [
"r137",
"r138",
"r142"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
"label": "Contract with Customer, Liability, Current",
"terseLabel": "Deferred revenue"
}
}
},
"localname": "ContractWithCustomerLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
"auth_ref": [
"r143"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
"label": "Contract with Customer, Liability, Revenue Recognized",
"terseLabel": "Revenue recognized in the period"
}
}
},
"localname": "ContractWithCustomerLiabilityRevenueRecognized",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostsAndExpenses": {
"auth_ref": [
"r55"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Total costs of sales and operating expenses for the period.",
"label": "Costs and Expenses",
"negatedTotalLabel": "Total operating expenses"
}
}
},
"localname": "CostsAndExpenses",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostsAndExpensesAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Costs and Expenses [Abstract]",
"terseLabel": "Operating expenses"
}
}
},
"localname": "CostsAndExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
"label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
"terseLabel": "Cumulative effect of applying new accounting standards"
}
}
},
"localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesBasisOfPresentationDetails",
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
"auth_ref": [
"r121"
],
"lang": {
"en-US": {
"role": {
"documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
"label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions, Greater than or Equal to One Year",
"terseLabel": "Number of available-for-sale securities in an unrealized loss position for more than one year"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
"auth_ref": [
"r109"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails": {
"order": 2.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
},
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Realized (gain) on available-for-sale debt securities",
"negatedLabel": "Realized (gain) loss on available-for-sale debt securities",
"terseLabel": "Gains (losses) on redemption or maturity of available-for-sale debt securities"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleRealizedGain",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails",
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails",
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
"auth_ref": [
"r109"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails": {
"order": 1.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": -1.0
},
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale, Realized Loss",
"negatedLabel": "Gains (losses) on redemption or maturity of available-for-sale debt securities",
"terseLabel": "Realized loss on available-for-sale debt securities"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails",
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails",
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleTable": {
"auth_ref": [
"r111"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale [Table]"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleTable",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
"auth_ref": [
"r111"
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale [Table Text Block]",
"terseLabel": "Schedule of investments in available-for-sale debt securities"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
"auth_ref": [
"r107",
"r120",
"r125"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
"label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
"terseLabel": "Fair market value of investments in an unrealized loss position"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
"auth_ref": [
"r108",
"r121"
],
"lang": {
"en-US": {
"role": {
"documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
"label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
"verboseLabel": "Number of debt securities"
}
}
},
"localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_DebtWeightedAverageInterestRate": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Weighted average interest rate of debt outstanding.",
"label": "Debt, Weighted Average Interest Rate",
"terseLabel": "Weighted average borrowing rate"
}
}
},
"localname": "DebtWeightedAverageInterestRate",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCorrectionOfImmaterialErrorDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_Depreciation": {
"auth_ref": [
"r66",
"r131"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
"label": "Depreciation",
"terseLabel": "Depreciation"
}
}
},
"localname": "Depreciation",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DisaggregationOfRevenueLineItems": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Disaggregation of Revenue [Line Items]",
"terseLabel": "Revenue"
}
}
},
"localname": "DisaggregationOfRevenueLineItems",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DisaggregationOfRevenueTable": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
"label": "Disaggregation of Revenue [Table]"
}
}
},
"localname": "DisaggregationOfRevenueTable",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"auth_ref": [
"r163"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for share-based payment arrangement.",
"label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
"terseLabel": "Share-based compensation"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Share-based compensation"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Loss per share",
"terseLabel": "Net loss per ordinary share - Basic and diluted"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasicAndDiluted": {
"auth_ref": [
"r77"
],
"lang": {
"en-US": {
"role": {
"documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Basic and Diluted",
"terseLabel": "Basic and diluted (in dollars per share)"
}
}
},
"localname": "EarningsPerShareBasicAndDiluted",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
"verboseLabel": "Antidilutive securities"
}
}
},
"localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareTextBlock": {
"auth_ref": [
"r80"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for earnings per share.",
"label": "Earnings Per Share [Text Block]",
"terseLabel": "Loss per share"
}
}
},
"localname": "EarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureLossPerShare"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r189"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 4.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
"terseLabel": "Effect of currency exchange rate changes on cash, cash equivalents and restricted cash"
}
}
},
"localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeRelatedLiabilitiesCurrent": {
"auth_ref": [
"r27"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
"order": 2.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Employee-related Liabilities, Current",
"terseLabel": "Accrued employee expenses"
}
}
},
"localname": "EmployeeRelatedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]",
"terseLabel": "Total share-based compensation expense included in the consolidated statements of operations"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r135"
],
"lang": {
"en-US": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
"terseLabel": "Assets and liabilities measured at fair value"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
"auth_ref": [
"r177",
"r178",
"r179",
"r184"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
"label": "Fair Value, Recurring and Nonrecurring [Table]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
"auth_ref": [
"r182"
],
"lang": {
"en-US": {
"role": {
"documentation": "Class of asset.",
"label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
"terseLabel": "Asset Class [Domain]"
}
}
},
"localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueByAssetClassAxis": {
"auth_ref": [
"r177",
"r184"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by class of asset.",
"label": "Asset Class [Axis]"
}
}
},
"localname": "FairValueByAssetClassAxis",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r147",
"r148",
"r149",
"r178",
"r205"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value Hierarchy and NAV [Axis]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementFrequencyAxis": {
"auth_ref": [
"r177",
"r178",
"r180",
"r181",
"r185"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by measurement frequency.",
"label": "Measurement Frequency [Axis]"
}
}
},
"localname": "FairValueByMeasurementFrequencyAxis",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Fair value measurements"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r183"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]",
"terseLabel": "Fair value measurements"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurements"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r147",
"r148",
"r149",
"r178",
"r206"
],
"lang": {
"en-US": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value Inputs Level1 [Member]",
"terseLabel": "Level 1"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r147",
"r148",
"r149",
"r178",
"r207"
],
"lang": {
"en-US": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value Inputs Level2 [Member]",
"terseLabel": "Level 2"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementFrequencyDomain": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Measurement frequency.",
"label": "Fair Value Measurement Frequency [Domain]",
"terseLabel": "Measurement Frequency [Domain]"
}
}
},
"localname": "FairValueMeasurementFrequencyDomain",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
"label": "Fair Value Measurement, Policy [Policy Text Block]",
"terseLabel": "Fair value measurements"
}
}
},
"localname": "FairValueMeasurementPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
"terseLabel": "Fair Value Hierarchy and NAV [Domain]"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsRecurringMember": {
"auth_ref": [
"r183",
"r185"
],
"lang": {
"en-US": {
"role": {
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
"label": "Fair Value Measurements Recurring [Member]",
"terseLabel": "Recurring basis"
}
}
},
"localname": "FairValueMeasurementsRecurringMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FinancialInstrumentAxis": {
"auth_ref": [
"r114",
"r115",
"r116",
"r117",
"r118",
"r122",
"r123",
"r124",
"r125"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by type of financial instrument.",
"label": "Financial Instrument [Axis]"
}
}
},
"localname": "FinancialInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
"auth_ref": [
"r186",
"r187",
"r188"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails": {
"order": 3.0,
"parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain (Loss), before Tax",
"verboseLabel": "Foreign exchange losses"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
"auth_ref": [
"r67",
"r186",
"r187",
"r188"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain (Loss), Unrealized",
"negatedLabel": "Unrealized foreign exchange losses"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossUnrealized",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r56"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
"order": 1.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General and Administrative Expense",
"negatedLabel": "General and administrative"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeneralAndAdministrativeExpenseMember": {
"auth_ref": [
"r54"
],
"lang": {
"en-US": {
"role": {
"documentation": "Primary financial statement caption encompassing general and administrative expense.",
"label": "General And Administrative Expense [Member]",
"terseLabel": "General and administrative"
}
}
},
"localname": "GeneralAndAdministrativeExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"auth_ref": [
"r52",
"r73",
"r209",
"r214",
"r223"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
"label": "Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest",
"totalLabel": "Loss before income taxes"
}
}
},
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r134"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]",
"terseLabel": "Income Statement Location [Domain]"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxExpenseBenefit": {
"auth_ref": [
"r70",
"r91",
"r165"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Income Tax Expense (Benefit)",
"negatedLabel": "Income taxes"
}
}
},
"localname": "IncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeTaxesReceivable": {
"auth_ref": [
"r31",
"r213",
"r221"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": {
"order": 2.0,
"parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
"label": "Income Taxes Receivable, Current",
"terseLabel": "Corporate tax receivable"
}
}
},
"localname": "IncomeTaxesReceivable",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]",
"terseLabel": "Changes in operating assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
"auth_ref": [
"r65"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
"label": "Other Liabilities and Prepayments",
"terseLabel": "Decrease in other liabilities and prepayments"
}
}
},
"localname": "IncreaseDecreaseInOtherAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
"auth_ref": [
"r65"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 10.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of increase (decrease) in operating assets classified as other.",
"label": "Increase (Decrease) in Noncurrent Assets",
"negatedLabel": "Decrease in non-current operating assets"
}
}
},
"localname": "IncreaseDecreaseInOtherOperatingAssets",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
"terseLabel": "Increase (Decrease) in Stockholders' Equity"
}
}
},
"localname": "IncreaseDecreaseInStockholdersEquityRollForward",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "stringItemType"
},
"us-gaap_IntangibleAssetsNetExcludingGoodwill": {
"auth_ref": [
"r127",
"r129"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 6.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
"label": "Intangible Assets, Net (Excluding Goodwill)",
"terseLabel": "Intangibles, net of accumulated amortization"
}
}
},
"localname": "IntangibleAssetsNetExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeInterest": {
"auth_ref": [
"r57",
"r90"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
"order": 3.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
"label": "Investment Income, Interest",
"terseLabel": "Interest income"
}
}
},
"localname": "InvestmentIncomeInterest",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
"auth_ref": [
"r111",
"r210",
"r216",
"r227"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for investments in certain debt and equity securities.",
"label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
"terseLabel": "Available-for-sale debt securities"
}
}
},
"localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecurities"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LeaseCost": {
"auth_ref": [
"r201",
"r203"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsLeaseCost": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of lease cost recognized by lessee for lease contract.",
"label": "Lease, Cost",
"totalLabel": "Total"
}
}
},
"localname": "LeaseCost",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsLeaseCost"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseCostTableTextBlock": {
"auth_ref": [
"r201"
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
"label": "Lease, Cost [Table Text Block]",
"terseLabel": "Schedule of lease cost"
}
}
},
"localname": "LeaseCostTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LeasesAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Operating leases"
}
}
},
"localname": "LeasesAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_LesseeLeasesPolicyTextBlock": {
"auth_ref": [
"r195"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
"label": "Lessee, Leases [Policy Text Block]",
"terseLabel": "Leases"
}
}
},
"localname": "LesseeLeasesPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
"auth_ref": [
"r202"
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
"label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
"terseLabel": "Schedule of maturities of operating lease liabilities"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesTables",
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
"auth_ref": [
"r202"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturitiesCalc2": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesMaturitiesDetailsCalc2": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
"label": "Lessee, Operating Lease, Liability, Payments, Due",
"totalLabel": "Total lease payments"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
"auth_ref": [
"r202"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities": {
"order": 1.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
"label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
"terseLabel": "after 2023"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
"auth_ref": [
"r202"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities": {
"order": 6.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
"label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
"terseLabel": "2019"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
"auth_ref": [
"r202"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities": {
"order": 2.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
"label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
"terseLabel": "2023"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
"auth_ref": [
"r202"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities": {
"order": 3.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
"label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
"terseLabel": "2022"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
"auth_ref": [
"r202"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities": {
"order": 4.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
"label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
"terseLabel": "2021"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
"auth_ref": [
"r202"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities": {
"order": 5.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
"label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
"terseLabel": "2020"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
"auth_ref": [
"r202"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturitiesCalc2": {
"order": 2.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
},
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesMaturitiesDetailsCalc2": {
"order": 1.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
"label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
"negatedLabel": "Less: Imputed interest"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeasesTextBlock": {
"auth_ref": [
"r204"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
"label": "Lessee, Operating Leases [Text Block]",
"terseLabel": "Operating leases"
}
}
},
"localname": "LesseeOperatingLeasesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeases"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r26"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r19",
"r212",
"r219"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total liabilities and stockholders' equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Liabilities and Equity [Abstract]",
"terseLabel": "Liabilities and stockholders' equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r28"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_MarketableSecuritiesAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Marketable Securities [Abstract]",
"terseLabel": "Marketable securities:"
}
}
},
"localname": "MarketableSecuritiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_NatureOfOperations": {
"auth_ref": [
"r81",
"r89"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
"label": "Nature of Operations [Text Block]",
"terseLabel": "General"
}
}
},
"localname": "NatureOfOperations",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureGeneral"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r63"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Net cash provided by financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
"terseLabel": "Cash flows from financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r63"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Net cash provided by investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
"terseLabel": "Cash flows from investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r63",
"r64",
"r67"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"totalLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Cash flows from operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r47",
"r49",
"r53",
"r67",
"r79",
"r215",
"r222"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
},
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income (Loss) Attributable to Parent",
"totalLabel": "Net loss attributable to ordinary shareholders",
"verboseLabel": "Net loss"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "New accounting pronouncements"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
"order": 1.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"totalLabel": "Operating loss"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseCost": {
"auth_ref": [
"r196",
"r203"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsLeaseCost": {
"order": 2.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
"label": "Operating Lease, Cost",
"terseLabel": "Operating lease cost"
}
}
},
"localname": "OperatingLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsLeaseCost",
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesCashFlowAndCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
}
}
},
"localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingLeaseLiability": {
"auth_ref": [
"r193"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturitiesCalc2": {
"order": 1.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
},
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesMaturitiesDetailsCalc2": {
"order": 2.0,
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
"label": "Operating Lease, Liability",
"totalLabel": "Present value of lease liability",
"verboseLabel": "Operating lease liability"
}
}
},
"localname": "OperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsMaturities",
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"auth_ref": [
"r193"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesBalanceSheetInformationDetails": {
"order": 2.0,
"parentTag": "adap_OperatingLeaseAssetLiabilityNet",
"weight": 1.0
},
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
"label": "Operating Lease, Liability, Current",
"negatedLabel": "Operating lease liabilities, current",
"terseLabel": "Operating lease liabilities, current"
}
}
},
"localname": "OperatingLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesBalanceSheetInformationDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r193"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesBalanceSheetInformationDetails": {
"order": 3.0,
"parentTag": "adap_OperatingLeaseAssetLiabilityNet",
"weight": 1.0
},
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating Lease, Liability, Noncurrent",
"negatedLabel": "Operating lease liabilities, non-current",
"terseLabel": "Operating lease liabilities, non-current"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesBalanceSheetInformationDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeasePayments": {
"auth_ref": [
"r194",
"r198"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
"label": "Operating Lease, Payments",
"terseLabel": "Operating cash flows from operating leases (in thousands)"
}
}
},
"localname": "OperatingLeasePayments",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsLeaseCost",
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesCashFlowAndCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r192"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesBalanceSheetInformationDetails": {
"order": 1.0,
"parentTag": "adap_OperatingLeaseAssetLiabilityNet",
"weight": -1.0
},
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Operating Lease, Right-of-Use Asset",
"terseLabel": "Operating lease right-of-use assets, net of accumulated amortization",
"verboseLabel": "Operating lease right-of-use assets"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesBalanceSheetInformationDetails",
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
"auth_ref": [
"r200",
"r203"
],
"lang": {
"en-US": {
"role": {
"documentation": "Weighted average discount rate for operating lease calculated at point in time.",
"label": "Operating Lease, Weighted Average Discount Rate, Percent",
"terseLabel": "Weighted-average discount rate - operating leases"
}
}
},
"localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsLeaseCost"
],
"xbrltype": "percentItemType"
},
"us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
"auth_ref": [
"r199",
"r203"
],
"lang": {
"en-US": {
"role": {
"documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Operating Lease, Weighted Average Remaining Lease Term",
"terseLabel": "Weighted-average remaining lease term - operating leases"
}
}
},
"localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsLeaseCost"
],
"xbrltype": "durationItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "General"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_OtherAccruedLiabilitiesCurrent": {
"auth_ref": [
"r8",
"r9",
"r10",
"r27"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
"order": 3.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Accrued Liabilities, Current",
"verboseLabel": "Other accrued expenditure"
}
}
},
"localname": "OtherAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsCurrent": {
"auth_ref": [
"r32"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": {
"order": 3.0,
"parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of current assets classified as other.",
"label": "Other Assets, Current",
"terseLabel": "Other current assets"
}
}
},
"localname": "OtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax [Abstract]",
"terseLabel": "Unrealized gains on available-for-sale debt securities"
}
}
},
"localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
"auth_ref": [
"r168",
"r169",
"r172"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss": {
"order": 2.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
"label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
"terseLabel": "Foreign currency translation adjustments, net of tax of $0, $0, $0 and $0"
}
}
},
"localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": {
"auth_ref": [
"r168",
"r169",
"r172"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
"label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent",
"terseLabel": "Foreign currency translation adjustments, tax"
}
}
},
"localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTaxAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Other Comprehensive Income (Loss), Available-for-sale Securities, before Reclassification Adjustments, Tax [Abstract]",
"terseLabel": "Other comprehensive income (loss), available-for-sale securities, before reclassification adjustments, tax"
}
}
},
"localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTaxAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquityParenthetical"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
"auth_ref": [
"r34",
"r190"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
"label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
"terseLabel": "Foreign currency translation adjustments"
}
}
},
"localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Accumulated other comprehensive income (loss)"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
"terseLabel": "Other comprehensive loss, net of tax"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": {
"auth_ref": [
"r40",
"r44",
"r45",
"r110"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
"label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax",
"terseLabel": "Reclassification adjustment for (gains) losses on available-for-sale debt securities"
}
}
},
"localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLossDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
"auth_ref": [
"r40",
"r44",
"r45",
"r110"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss": {
"order": 3.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
"label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
"negatedLabel": "Reclassification adjustment for (gains) losses on available-for-sale debt securities included in net loss, net of tax of $0, $0, $0 and $0"
}
}
},
"localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
"auth_ref": [
"r41",
"r110"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
"label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
"terseLabel": "Reclassification from accumulated other comprehensive income of gains on available-for-sale debt securities included in net income, tax",
"verboseLabel": "Reclassification adjustment for losses on available-for-sale debt securities included in net loss, tax"
}
}
},
"localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquityParenthetical",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax": {
"auth_ref": [
"r40",
"r44",
"r45"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized loss realized upon the write-down of available-for-sale securities.",
"label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax",
"terseLabel": "Reclassification from accumulated other comprehensive income of gains on available-for-sale debt securities included in net income, net of tax of $"
}
}
},
"localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax": {
"auth_ref": [
"r45",
"r112"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for unrealized gain (loss) of investment classified as available-for-sale transferred to equity method.",
"label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Investment Transferred from Available-for-sale to Equity Method, after Tax",
"negatedLabel": "Reclassification from accumulated other comprehensive income of gains on available-for-sale debt securities included in net income, net of tax of $"
}
}
},
"localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodAfterTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
"auth_ref": [
"r36",
"r40"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss": {
"order": 4.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
"label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax",
"terseLabel": "Unrealized holding gains on available-for-sale debt securities, net of tax of $0, $0, $0 and $0",
"verboseLabel": "Unrealized holding gains (losses) on available-for-sale debt securities, net of tax of $0"
}
}
},
"localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLoss"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
"auth_ref": [
"r37",
"r41"
],
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
"label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax",
"terseLabel": "Unrealized holding gains on available-for-sale debt securities, tax",
"verboseLabel": "Unrealized holding gains on available-for-sale debt securities, tax"
}
}
},
"localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquityParenthetical",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfComprehensiveLossParenthetical"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherCurrentAssetsTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for other current assets.",
"label": "Other Current Assets [Text Block]",
"terseLabel": "Other current assets"
}
}
},
"localname": "OtherCurrentAssetsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssets"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherLiabilitiesCurrent": {
"auth_ref": [
"r7",
"r8",
"r27"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
"order": 4.0,
"parentTag": "us-gaap_AccruedLiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Current",
"terseLabel": "Other"
}
}
},
"localname": "OtherLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilitiesNoncurrent": {
"auth_ref": [
"r29"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Noncurrent",
"terseLabel": "Other liabilities, non-current"
}
}
},
"localname": "OtherLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
"label": "Other Nonoperating Income and Expense [Text Block]",
"terseLabel": "Other income, net"
}
}
},
"localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNet"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r58"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
"order": 2.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income (Expense)",
"terseLabel": "Other expense, net",
"totalLabel": "Other income, net"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Other expense, net"
}
}
},
"localname": "OtherNonoperatingIncomeExpenseAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_OtherOperatingActivitiesCashFlowStatement": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
"label": "Other Operating Activities, Cash Flow Statement",
"terseLabel": "Other"
}
}
},
"localname": "OtherOperatingActivitiesCashFlowStatement",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireIntangibleAssets": {
"auth_ref": [
"r60"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
"label": "Payments to Acquire Intangible Assets",
"negatedLabel": "Acquisition of intangibles"
}
}
},
"localname": "PaymentsToAcquireIntangibleAssets",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireMarketableSecurities": {
"auth_ref": [
"r101"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash outflow for purchase of marketable security.",
"label": "Payments to Acquire Marketable Securities",
"negatedLabel": "Investment in marketable securities"
}
}
},
"localname": "PaymentsToAcquireMarketableSecurities",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"auth_ref": [
"r60"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
"label": "Payments to Acquire Property, Plant, and Equipment",
"negatedLabel": "Acquisition of property, plant and equipment"
}
}
},
"localname": "PaymentsToAcquirePropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
"auth_ref": [
"r3",
"r21",
"r22"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense and Other Assets, Current",
"terseLabel": "Other current assets and prepaid expenses (including current portion of clinical materials)",
"totalLabel": "Total"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Other current assets"
}
}
},
"localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_PrepaidExpenseCurrent": {
"auth_ref": [
"r2",
"r4",
"r126"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": {
"order": 4.0,
"parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense, Current",
"terseLabel": "Prepayments"
}
}
},
"localname": "PrepaidExpenseCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
"label": "Proceeds from Sale and Maturity of Marketable Securities",
"verboseLabel": "Maturity or redemption of marketable securities"
}
}
},
"localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockOptionsExercised": {
"auth_ref": [
"r61",
"r159"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
"label": "Proceeds from Stock Options Exercised",
"terseLabel": "Proceeds from exercise of stock options"
}
}
},
"localname": "ProceedsFromStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProfitLoss": {
"auth_ref": [
"r47",
"r49",
"r62",
"r92",
"r93",
"r168",
"r170",
"r171",
"r175",
"r176"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
"label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
"terseLabel": "Net loss"
}
}
},
"localname": "ProfitLoss",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r11",
"r12",
"r133",
"r220"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net.",
"terseLabel": "Property, plant and equipment, net of accumulated depreciation of $19,528 (2018: $15,924)"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
"terseLabel": "Schedule of amounts reclassified out of other comprehensive income"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLossTables",
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r164",
"r229"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
"order": 2.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and Development Expense",
"negatedLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpenseMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
"label": "Research And Development Expense [Member]",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
"auth_ref": [
"r6",
"r13",
"r68",
"r69",
"r228"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Restricted Cash and Cash Equivalents, Noncurrent",
"terseLabel": "Restricted cash"
}
}
},
"localname": "RestrictedCashAndCashEquivalentsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r18",
"r136",
"r218"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings (Accumulated Deficit)",
"negatedLabel": "Accumulated deficit",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureGeneralDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "Accumulated deficit"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Revenue"
}
}
},
"localname": "RevenueFromContractWithCustomerAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
"auth_ref": [
"r140",
"r141"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
"label": "Revenue from Contract with Customer, Excluding Assessed Tax",
"negatedTerseLabel": "Revenue in the period",
"terseLabel": "Revenue"
}
}
},
"localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueFromContractWithCustomerTextBlock": {
"auth_ref": [
"r146"
],
"lang": {
"en-US": {
"role": {
"documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
"label": "Revenue from Contract with Customer [Text Block]",
"terseLabel": "Revenue"
}
}
},
"localname": "RevenueFromContractWithCustomerTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenue"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of the components of accrued liabilities.",
"label": "Schedule of Accrued Liabilities [Table Text Block]",
"terseLabel": "Schedule of accrued expenses and other current liabilities"
}
}
},
"localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"auth_ref": [
"r78"
],
"lang": {
"en-US": {
"role": {
"documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureLossPerShareAntidilutiveSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Schedule of Available-for-sale Securities [Line Items]"
}
}
},
"localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
"auth_ref": [
"r151",
"r157",
"r160"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
"label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
"auth_ref": [
"r151",
"r157",
"r160"
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
"label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
"verboseLabel": "Summary of share-based compensation expense included in the unaudited consolidated statements of operations"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
"auth_ref": [
"r177",
"r178"
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
"terseLabel": "Summary of fair value of assets and liabilities on a recurring basis based on fair value measurement criteria"
}
}
},
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of the carrying amounts of other current assets.",
"label": "Schedule of Other Current Assets [Table Text Block]",
"terseLabel": "Summary of other current assets"
}
}
},
"localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
"label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
"terseLabel": "Schedule of other expense, net"
}
}
},
"localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherExpenseNetTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
"auth_ref": [
"r152",
"r154",
"r156"
],
"lang": {
"en-US": {
"role": {
"documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
"label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]",
"terseLabel": "Summary of share options and options which have a nominal exercise price"
}
}
},
"localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r65"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows": {
"order": 11.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share-based Compensation.",
"terseLabel": "Share-based compensation expense"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementConsolidatedStatementsOfCashFlows"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
"terseLabel": "Number of options granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r155"
],
"lang": {
"en-US": {
"role": {
"documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Weighted average fair value (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureShareBasedCompensationOptionsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShortTermLeaseCost": {
"auth_ref": [
"r197",
"r203"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsLeaseCost": {
"order": 1.0,
"parentTag": "us-gaap_LeaseCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
"label": "Short-term Lease, Cost",
"terseLabel": "Short-term lease cost"
}
}
},
"localname": "ShortTermLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOperatingLeasesDetailsLeaseCost",
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesCashFlowAndCostDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r30",
"r135"
],
"lang": {
"en-US": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]",
"terseLabel": "Statement"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS"
}
}
},
"localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGE IN EQUITY"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"auth_ref": [
"r14",
"r15",
"r135",
"r136",
"r153"
],
"lang": {
"en-US": {
"role": {
"documentation": "Number of share options (or share units) exercised during the current period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
"netLabel": "Issuance of shares upon exercise of stock options (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
"auth_ref": [
"r30",
"r135",
"r136"
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Value of stock issued as a result of the exercise of stock options.",
"label": "Stock Issued During Period, Value, Stock Options Exercised",
"verboseLabel": "Issuance of shares upon exercise of stock options"
}
}
},
"localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Stockholders' Equity Attributable to Parent [Abstract]",
"terseLabel": "Stockholders' equity"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
"auth_ref": [
"r166",
"r167",
"r174"
],
"calculation": {
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
"label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
"periodEndLabel": "Balance at the end of the period",
"periodStartLabel": "Balance at the beginning of the period",
"totalLabel": "Total stockholders' equity"
}
}
},
"localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedBalanceSheets",
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of stockholders' equity including the portion attributable to noncontrolling interests, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
"label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance",
"terseLabel": "Beginning balance as adjusted"
}
}
},
"localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementOfChangeInEquity"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_TradingSecuritiesDebt": {
"auth_ref": [
"r99",
"r100"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails": {
"order": 2.0,
"parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
"label": "Trading Securities, Debt",
"terseLabel": "Corporate debt securities"
}
}
},
"localname": "TradingSecuritiesDebt",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
"auth_ref": [
"r208"
],
"lang": {
"en-US": {
"role": {
"documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
"label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
"terseLabel": "Financial Instruments [Domain]"
}
}
},
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureAvailableForSaleDebtSecuritiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TypeOfAdoptionMember": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
"label": "Type Of Adoption [Member]",
"terseLabel": "Type of Adoption [Domain]"
}
}
},
"localname": "TypeOfAdoptionMember",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLeasesGeneralInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TypeOfRevenueExtensibleList": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
"label": "Revenue, Product and Service [Extensible List]",
"terseLabel": "Revenue, Product and Service [Extensible List]"
}
}
},
"localname": "TypeOfRevenueExtensibleList",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureRevenueRevenueFromContractsWithCustomersDetails"
],
"xbrltype": "extensibleListItemType"
},
"us-gaap_USGovernmentSecuritiesAtCarryingValue": {
"auth_ref": [
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails": {
"order": 3.0,
"parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
"label": "US Government Securities, at Carrying Value",
"terseLabel": "Agency bond"
}
}
},
"localname": "USGovernmentSecuritiesAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureFairValueMeasurementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_UseOfEstimates": {
"auth_ref": [
"r82",
"r83",
"r84",
"r85",
"r86",
"r87",
"r88"
],
"lang": {
"en-US": {
"role": {
"documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
"label": "Use of Estimates, Policy [Policy Text Block]",
"terseLabel": "Use of estimates in financial statements"
}
}
},
"localname": "UseOfEstimates",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ValueAddedTaxReceivableCurrent": {
"auth_ref": [
"r32"
],
"calculation": {
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails": {
"order": 5.0,
"parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-US": {
"role": {
"documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
"label": "Value Added Tax Receivable, Current",
"terseLabel": "VAT receivable"
}
}
},
"localname": "ValueAddedTaxReceivableCurrent",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/DisclosureOtherCurrentAssetsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
"label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
"terseLabel": "Basic and diluted (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
"auth_ref": [
],
"lang": {
"en-US": {
"role": {
"label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
"terseLabel": "Weighted average shares outstanding:"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
"nsuri": "http://fasb.org/us-gaap/2019-01-31",
"presentation": [
"http://www.adaptimmune.com/role/StatementUnauditedCondensedConsolidatedStatementsOfOperations"
],
"xbrltype": "stringItemType"
}
},
"unitCount": 9
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(aa)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(13))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
},
"r111": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "320",
"URI": "http://asc.fasb.org/topic&trid=2196928"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "33",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "323",
"URI": "http://asc.fasb.org/extlink&oid=118954474&loc=d3e32804-111569"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(14))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b)(3)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Topic": "340",
"URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "((a)(1),(b))",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(2)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
},
"r146": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "606",
"URI": "http://asc.fasb.org/topic&trid=49130388"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "2A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.F)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
},
"r163": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "718",
"URI": "http://asc.fasb.org/topic&trid=2228938"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(3)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "4I",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "4J",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "4K",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(1)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b,c)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(1)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(3)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(4)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(4)",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "53",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "842",
"URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
},
"r204": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "20",
"Topic": "842",
"URI": "http://asc.fasb.org/subtopic&trid=77888251"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "50",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "940",
"URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(7))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "320",
"Topic": "940",
"URI": "http://asc.fasb.org/subtopic&trid=2176304"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.10)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(15))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
},
"r216": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "320",
"Topic": "942",
"URI": "http://asc.fasb.org/subtopic&trid=2209399"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(8))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.5(c))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(8))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "4H",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(c)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
},
"r227": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"SubTopic": "320",
"Topic": "946",
"URI": "http://asc.fasb.org/subtopic&trid=2324412"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "210",
"Topic": "954",
"URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.1)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r230": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r231": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r232": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-13"
},
"r233": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1-"
},
"r234": {
"Name": "Regulation 12B",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r235": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.14)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.24)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.3(a)(4))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.8)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.9)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a),(b),(c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "17A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "17B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(10))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(4))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7(b))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
},
"r59": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "220",
"URI": "http://asc.fasb.org/topic&trid=2134417"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
},
"r71": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "http://asc.fasb.org/topic&trid=2122369"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
},
"r80": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "260",
"URI": "http://asc.fasb.org/topic&trid=2144383"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
},
"r89": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "275",
"URI": "http://asc.fasb.org/topic&trid=2134479"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
}
},
"version": "2.1"
} |
